Author

Janette E. Sutton

Observed names: J E Sutton, Janette E Sutton, Janette Sutton

Observed institutions: Roche (United States), Pfizer (United States), Allogene Therapeutics (United States)

ORCID: 0000-0002-4580-9319

Observed ORCID: 0000-0002-4580-9319

OpenAlex ID: A5072045494

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

2015 · Pavel Strop, Kathy Delaria, et al. · Nature Biotechnology · 182

Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9

2012 · Javier Chaparro-Riggers, Hong Liang, et al. · Journal of Biological Chemistry · 166

PDF

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma

2019 · Cesar Sommer, Bijan Boldajipour, et al. · Molecular Therapy · 152

PDF

Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair

2012 · Pavel Strop, Wei-Hsien Ho, et al. · Journal of Molecular Biology · 142

Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates

2011 · Hong Liang, Javier Chaparro-Riggers, et al. · Journal of Pharmacology and Experimental Therapeutics · 106

Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

2020 · Cesar Sommer, Hsin-Yuan Cheng, et al. · Molecular Therapy · 103

PDF

CGRP function‐blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat

2008 · J Zeller, K T Poulsen, et al. · British Journal of Pharmacology · 92

PDF

Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates

2017 · Rachel M. DeVay, Kathy Delaria, et al. · Bioconjugate Chemistry · 67

Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy

2015 · Magdalena Dorywalska, Pavel Strop, et al. · PLoS ONE · 61

PDF

Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer

2023 · Yi Zhang, Silvia K. Tacheva-Grigorova, et al. · Clinical Cancer Research · 55

Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: Lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice

2009 · Jordan A. Mechanic, Janette E. Sutton, et al. · European Neuropsychopharmacology · 44

ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma

2018 · Cesar Sommer, Bijan Boldajipour, et al. · Blood · 16

Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models

2023 · Regina J. Lin, Janette Sutton, et al. · Science Advances · 14

PDF

Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar TTM Cell Therapy for the Treatment of Multiple Myeloma

2020 · Cesar Sommer, Regina Lin, et al. · Blood · 10

Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling

2022 · Regina J. Lin, Andrew R. Nager, et al. · Cancer Immunology Research · 8

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

2019 · Cesar Sommer, Hsin-Yuan Cheng, et al. · Blood · 4

Off-the-shelf AlloCAR T™ cells targeting BCMA for the treatment of multiple myeloma

2019 · Cesar Sommer, Trevor Bentley, et al. · Clinical Lymphoma Myeloma & Leukemia · 3

Abstract 1519: PD1 TurboCAR™ T cells: PD1-resistant CAR T cells with programmable cytokine signaling outputs

2021 · Regina Lin, Yi Zhang, et al. · Cancer Research · 1

68 LNK001 is a High-Fidelity AND-Logic-Gated CAR T Cell Therapy that Enables Precision Targeting of Clear Cell Renal Cell Carcinoma (ccRCC): Target Discovery and Validation for the ATHENA Phase 1 Trial

2026 · Alexander Bankovich, Bryan Smith, et al. · The Oncologist

PDF

83 Preclinical Evaluation of LNK001: Stringent AND-Gate Fidelity and Potent Efficacy of a Dual-Antigen CAIX/ENPP3 CAR T Cell Therapy for Clear Cell Renal Cell Carcinoma

2026 · Mark Wallet, Rebecca Larson, et al. · The Oncologist

PDF

Figure FS2 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer